JP2017525755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525755A5 JP2017525755A5 JP2017519448A JP2017519448A JP2017525755A5 JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5 JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- linker
- compound according
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005647 linker group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000001413 amino acids Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000006850 spacer group Chemical group 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 229960003646 lysine Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000051957 human ERBB2 Human genes 0.000 claims 3
- 229920000768 polyamine Polymers 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 235000013477 citrulline Nutrition 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960002429 proline Drugs 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- DLGAUVSRZXNATA-DHYYHALDSA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.CC[C@H](C)[C@H](N)C(O)=O DLGAUVSRZXNATA-DHYYHALDSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010062122 Testicular choriocarcinoma Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 208000014911 choriocarcinoma of testis Diseases 0.000 claims 1
- 201000000336 choriocarcinoma of the testis Diseases 0.000 claims 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- -1 tubricin Chemical compound 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014912P | 2014-06-20 | 2014-06-20 | |
| US62/014,912 | 2014-06-20 | ||
| US201462015661P | 2014-06-23 | 2014-06-23 | |
| US62/015,661 | 2014-06-23 | ||
| PCT/US2015/036414 WO2015195904A1 (en) | 2014-06-20 | 2015-06-18 | Her2 antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017525755A JP2017525755A (ja) | 2017-09-07 |
| JP2017525755A5 true JP2017525755A5 (enExample) | 2018-07-26 |
Family
ID=54936097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519448A Pending JP2017525755A (ja) | 2014-06-20 | 2015-06-18 | Ｈｅｒ２抗体−薬物抱合体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160051695A1 (enExample) |
| EP (1) | EP3157560A4 (enExample) |
| JP (1) | JP2017525755A (enExample) |
| KR (1) | KR20170063507A (enExample) |
| CN (1) | CN106659783A (enExample) |
| AU (1) | AU2015277100A1 (enExample) |
| BR (1) | BR112016029588A2 (enExample) |
| CA (1) | CA2952834A1 (enExample) |
| IL (1) | IL249626A0 (enExample) |
| MX (1) | MX2016017117A (enExample) |
| PH (1) | PH12016502509A1 (enExample) |
| RU (1) | RU2017101331A (enExample) |
| SG (2) | SG11201610468XA (enExample) |
| TW (1) | TW201625315A (enExample) |
| WO (1) | WO2015195904A1 (enExample) |
| ZA (1) | ZA201700306B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953106B2 (en) | 2015-02-16 | 2021-03-23 | Lonza Ltd | Antibodies |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3925978A1 (en) | 2011-06-13 | 2021-12-22 | AltruBio Inc. | Anti-psgl-1 antibodies and uses thereof |
| CN108546283A (zh) | 2012-12-21 | 2018-09-18 | 荷商台医(有限合伙)公司 | 亲水性自消耗连接子及其缀合物 |
| US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
| HRP20201790T1 (hr) * | 2015-06-29 | 2021-02-05 | Immunogen, Inc. | Konjugati cisteinom izmijenjenih antitijela |
| MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017109619A1 (en) * | 2015-12-21 | 2017-06-29 | Pfizer Inc. | Purification of antibody drug conjugates using a sodium phosphate gradient |
| US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| NZ756323A (en) * | 2017-02-28 | 2022-07-01 | Seagen Inc | Cysteine mutated antibodies for conjugation |
| EP4011396A1 (en) | 2017-03-10 | 2022-06-15 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
| CA3066920C (en) * | 2017-06-16 | 2024-07-02 | Eli Lilly And Company | COMPOUNDS OF MODIFIED ANTIBODY AND CONJUGATES OF THESE |
| SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| AU2019232652B2 (en) * | 2018-03-09 | 2022-04-21 | Quiapeg Pharmaceuticals Ab | Releasable antibody conjugates |
| EP3833690B1 (en) * | 2018-08-08 | 2024-03-27 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recombinant bifunctional protein targeting cd47 and her2 |
| AU2019340366B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US11357828B2 (en) | 2018-09-12 | 2022-06-14 | Quiapeg Pharmaceuticals Ab | Releasable GLP-1 conjugates |
| KR20220003506A (ko) * | 2019-03-22 | 2022-01-10 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 표적 분자의 변형을 위한 조성물 및 방법 |
| AU2021232625A1 (en) * | 2020-03-05 | 2022-09-29 | Umc Utrecht Holding B.V. | Membrane ubiquitin ligases to target protein degradation |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| CN112618726B (zh) * | 2020-12-21 | 2022-11-11 | 江南大学 | 一种抗体缀合物、增强抗体分子免疫效应功能的方法 |
| IL305883A (en) | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective release of drugs from internalized conjugates of biologically active compounds |
| AU2024256916A1 (en) | 2023-04-18 | 2025-12-04 | Astrazeneca Ab | Conjugates comprising cleavable linkers |
| WO2025059190A2 (en) * | 2023-09-11 | 2025-03-20 | Catena Biosciences, Inc. | Polypeptide conjugation compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394083B (zh) * | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7662936B2 (en) * | 2004-04-07 | 2010-02-16 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| WO2010111018A1 (en) * | 2009-03-06 | 2010-09-30 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| CN102802661B (zh) * | 2009-06-22 | 2016-01-13 | 米迪缪尼有限公司 | 用于位点特异性偶联的工程改造的Fc区 |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| JP5972864B2 (ja) * | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
| MX374267B (es) * | 2010-04-21 | 2025-03-06 | Syntarga Bv | Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales. |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CN108546283A (zh) * | 2012-12-21 | 2018-09-18 | 荷商台医(有限合伙)公司 | 亲水性自消耗连接子及其缀合物 |
| SG10201706468RA (en) * | 2013-02-08 | 2017-09-28 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| MX368396B (es) * | 2014-01-10 | 2019-10-01 | Synthon Biopharmaceuticals Bv | Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. |
-
2015
- 2015-06-18 WO PCT/US2015/036414 patent/WO2015195904A1/en not_active Ceased
- 2015-06-18 US US14/743,351 patent/US20160051695A1/en not_active Abandoned
- 2015-06-18 SG SG11201610468XA patent/SG11201610468XA/en unknown
- 2015-06-18 CA CA2952834A patent/CA2952834A1/en not_active Abandoned
- 2015-06-18 SG SG10201811124YA patent/SG10201811124YA/en unknown
- 2015-06-18 EP EP15809482.1A patent/EP3157560A4/en not_active Withdrawn
- 2015-06-18 JP JP2017519448A patent/JP2017525755A/ja active Pending
- 2015-06-18 AU AU2015277100A patent/AU2015277100A1/en not_active Abandoned
- 2015-06-18 TW TW104119839A patent/TW201625315A/zh unknown
- 2015-06-18 CN CN201580043407.5A patent/CN106659783A/zh active Pending
- 2015-06-18 MX MX2016017117A patent/MX2016017117A/es unknown
- 2015-06-18 RU RU2017101331A patent/RU2017101331A/ru not_active Application Discontinuation
- 2015-06-18 KR KR1020177001643A patent/KR20170063507A/ko not_active Withdrawn
- 2015-06-18 BR BR112016029588A patent/BR112016029588A2/pt not_active IP Right Cessation
-
2016
- 2016-12-15 PH PH12016502509A patent/PH12016502509A1/en unknown
- 2016-12-18 IL IL249626A patent/IL249626A0/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00306A patent/ZA201700306B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953106B2 (en) | 2015-02-16 | 2021-03-23 | Lonza Ltd | Antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525755A5 (enExample) | ||
| RU2017101331A (ru) | Конъюгаты антитело к her2 - лекарственное средство | |
| US12285491B2 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | |
| AU2021266317B2 (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
| JP2016508136A5 (enExample) | ||
| RU2017101662A (ru) | Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения | |
| RU2015129800A (ru) | Гидрофильные саморазрушающиеся линкеры и их конъюгаты | |
| KR102655301B1 (ko) | 비스-링키지를 사용한 세포독성 약물의 접합 | |
| KR20240095316A (ko) | Bcma 단일클론 항체 및 항체-약물 접합체 | |
| RU2017101681A (ru) | Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения | |
| JP2017528418A5 (enExample) | ||
| JP2023530128A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| JP2024510435A (ja) | 生体活性化合物の内部移行複合体からの選択的薬物放出 | |
| JP2024511360A (ja) | 生体活性化合物の内部移行複合体からの選択的薬物放出 | |
| JP2012522513A5 (enExample) | ||
| JP2012522512A5 (enExample) | ||
| KR20210117302A (ko) | 분지형 링커를 갖는 아마니타 독소의 접합체 | |
| WO2015112822A1 (en) | Antibody-drug conjugates targeting kit receptor and uses thereof | |
| IL298053A (en) | Antibody-drug conjugates against bcma and methods of use | |
| JPWO2023046202A5 (enExample) | ||
| WO2020065408A1 (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| CN117120097A (zh) | 内化的生物活性化合物缀合物的选择性药物释放 | |
| CN117120098A (zh) | 内化的生物活性化合物缀合物的选择性药物释放 | |
| HK40107212A (zh) | 内化的生物活性化合物缀合物的选择性药物释放 | |
| NZ744940B2 (en) | Conjugation linkers, antibody-drug conjugates thereof, and methods of synthesis and use of such conjugates |